Sign In
Buy TAK
$17.09
-0.160 (-0.93%)
At Close: Jul 31, 2026
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the P
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
07:30am, Tuesday, 27'th May 2025
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Applications are now open for the Takeda Innovators in Science Award with Nature recognizing the groundbreaking research of early-career scientists.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) i
Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise
08:30am, Sunday, 11'th May 2025
Takeda Pharmaceuticals showed strong revenue and operating income growth in FY2024, despite challenges from Vyvanse generics and US insurance issues. New guidance for FY2025 is slightly lower due to e
Top 4 GARP Stocks With Attractive PEG Ratios to Watch
04:00pm, Friday, 09'th May 2025
Here we present four high-growth GARP picks based on discounted PEG. These are PAK, FIVN, LTM and MFG.
Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript
09:26am, Friday, 09'th May 2025
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2024 Results Conference Call May 8, 2025 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - Preside
Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO
11:54pm, Thursday, 08'th May 2025
Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drug
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs
10:32am, Thursday, 08'th May 2025
Takeda Pharmaceutical Company Limited TAK reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year.
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Produ
Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 07'th May 2025
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
10:45am, Wednesday, 07'th May 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
08:00am, Monday, 05'th May 2025
BANNOCKBURN, Ill.--(BUSINESS WIRE)--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S.
TAK or DSNKY: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 02'nd May 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice
01:01pm, Wednesday, 30'th Apr 2025
Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Value Stocks to Buy for April 30th
10:35am, Wednesday, 30'th Apr 2025
SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025.
